Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) originally entered the market for the treatment of type 2 diabetes (T2D) in 2005 with the approval of exenatide (Byetta; Bristol Myers Squibb). In the past 20 years, GLP-1 RAs have gained…
Redefining the Role of GLP-1 Therapies: The Clinical Trials Behind the Expanding Indications
